The U.S. Food and Drug Administration declined to approve Lipocine Inc.’s oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer’s shares down 34 percent.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-11-11 06:57:532019-11-11 12:54:33FDA rejects Lipocine’s testosterone drug for third time